ARCT - NASDAQ
Arcturus Therapeutics Holdings Inc.
$7.60
+0.80%Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
At a Glance
Live SnapshotArcturus Therapeutics Holdings Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Arcturus Therapeutics Holdings Inc. Income Statement
ARCT • NASDAQ
| Arcturus Therapeutics Holdings Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||
67.2M | 138.4M | 157.7M | 205.8M | 12.4M | 9.5M | 20.8M | 15.8M | 13M | 20.4M | 6.1M | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||||||||
(3M) | (0.0) | (0.0) | (0.0) | (0.0) | (55.9M) | (32.4M) | (17M) | (410K) | (294K) | (51K) | (0.0) | (0.0) | (0.0) | (0.0) | |
64.2M | 138.4M | 157.7M | 205.8M | 12.4M | -46.4M | -11.7M | -1.2M | 12.6M | 20.1M | 6.1M | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | |||||||||||||||
(139.2M) | (234.1M) | (236M) | (193.6M) | (215.2M) | (25.1M) | (46.3M) | (37.6M) | (23.5M) | (25.2M) | (19.7M) | (33.1M) | (10.3M) | (1.5M) | (3.9M) | |
(46.1M) | (52.8M) | (52.9M) | (46.1M) | (41.5M) | (25.1M) | (12.7M) | (20.6M) | (7.6M) | (5.4M) | (5M) | (5.8M) | (3.2M) | (683K) | (2.1M) | |
(112.2M) | (195.2M) | (192.1M) | (147.8M) | (173.8M) | (57.8M) | (33.6M) | (17M) | (15.9M) | (18.4M) | (13.5M) | (25.1M) | (7.1M) | (818K) | (1.8M) | |
-75M | -95.7M | -78.2M | 12.2M | -202.9M | -71.5M | -25.5M | -21.8M | -10.5M | -25.2M | -19.7M | -33.1M | -10.3M | -1.5M | -3.9M | |
PRE-TAX INCOME | |||||||||||||||
(0.0) | (0.0) | (767K) | (3M) | (2.7M) | (831K) | (854K) | (186K) | (150K) | (295K) | (251K) | (2K) | (197K) | (80K) | (44K) | |
10.1M | 15.2M | 16.6M | -420K | -1.9M | -361K | -446K | 328K | -61K | -286K | -250K | 237K | -175K | -78K | -23K | |
-19.1M | -13.9M | -9.1M | -244K | (0.0) | -57.8M | (0.0) | (0.0) | -348K | (1.4M) | (1.2M) | (2.1M) | (0.0) | (0.0) | (0.0) | |
9.2M | 14.7M | 50.3M | -1.5M | -822K | -624K | -478K | 26K | -409K | -536K | 11K | 227K | -197K | -78K | -23K | |
-65.8M | -80.9M | -27.9M | 10.6M | -203.7M | -72.1M | -26M | -21.8M | -10.9M | -24.5M | -19.4M | -32.9M | -10.5M | -1.6M | -3.9M | |
NET INCOME | |||||||||||||||
(0.0) | -4K | (1.8M) | (1.3M) | (0.0) | (0.0) | -270K | (212K) | (1K) | (73K) | (51K) | -17K | (61K) | (0.0) | (21K) | |
-65.8M | -80.9M | -29.7M | 9.3M | -203.7M | -72.1M | -26M | -21.8M | -10.9M | -24.6M | -19.4M | -32.8M | -10.5M | -1.6M | -3.9M |
SEC Filings
ARCT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 01, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | December 30, 2025 | December 30, 2025 | ||
8-K 8-K 2025 N/A | December 15, 2025 | December 11, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 22, 2025 | October 22, 2025 | 2025 |
Related Guides
Continue your ARCT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.